MLYS
Mineralys Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.33B
P/E Ratio
—
EPS
$-2.29
Beta
0.69
52W High
$47.65
52W Low
$11.48
50-Day MA
$28.01
200-Day MA
$29.66
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-170.54M |
| Operating Margin | 0.00% |
| Return on Equity | -36.90% |
| Return on Assets | -24.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.93 |
| Price-to-Book | 3.44 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -7.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $82.40M |
| Float | $60.53M |
| % Insiders | 1.71% |
| % Institutions | 113.64% |
Analyst Ratings
Consensus ($49.38 target)
8
Buy1
HoldData last updated: 4/8/2026